Anal cancer
Normal tissue BRCA1 promoter methylation is positively associated with risk for high-grade serous ovarian cancer
The role of normal tissue gene promoter methylation in cancer risk is poorly understood. A study has evaluated associations between normal...
Clonal hematopoiesis may be a modifiable risk factor for atherosclerotic cardiovascular disease
Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...
Breast cancer, drug treatments are often stopped five years after removal of the primary tumour. These women are still at risk of relapse
The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the...
PROSPER trial: Enzalutamide reduces the risk of metastasis or death by 71% in men with non-metastatic castration-resistant prostate cancer
The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...
SPARTAN trial, Apalutamide, an androgen receptor inhibitor, improves median metastasis-free survival by more than two years in patients with non-metastatic castration-resistant prostate cancer
New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...
FDA has approved Erleada, a new treatment for non-metastatic castration-resistant prostate cancer
The FDA ( U.S. Food and Drug Administration ) has approved Erleada ( Apalutamide ) for the treatment of patients...
Revlimid as monotherapy for the maintenance treatment of patients with newly diagnosed multiple myeloma after autologous stem cell transplantation, approved in European Union
The European Commission ( EC ) has approved Revlimid ( Lenalidomide ) as monotherapy for the maintenance treatment of adult...
Carfilzomib significantly improves overall survival compared to Bortezomib in relapsed or refractory multiple myeloma patients
Positive results from a planned overall survival ( OS ) interim analysis of the phase 3 head-to-head ENDEAVOR trial were...
Kisqali approved by FDA in combination with an aromatase inhibitor for the frontline treatment of postmenopausal women with HR–positive, HER2-negative advanced breast cancer
The CDK 4/6 inhibitor Ribociclib ( Kisqali ) has been approved by the FDA ( Food and Drug Administration )...
Microbiome and response to cancer immunotherapy, a link found
Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the...
Anaplastic large cell lymphoma associated with breast implant
In 2011, the FDA ( Food and Drug Administration ) identified a possible association between breast implants and the development...
Prostate cancer: link between androgen deprivation therapy and dementia
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...
No evidence of cytomegalovirus in aggressive brain cancer tissue
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say...
Shorter sleep duration is associated with increased risk of fatal prostate cancer in younger men
Shorter sleep duration was associated with increased risk of death from prostate cancer in men under the age of 65. There...
Relapsed B-cell acute lymphoblastic leukemia: durability of CAR T-cell therapy response may depend on pretreatment disease burden
Although most patients with relapsed B-cell acute lymphoblastic leukemia ( B-ALL ) experienced complete response after treatment with a type...
Chemoprevention of colorectal cancer: potential biomarkers that predict for Celecoxib identified
Ten years ago, the Adenoma Prevention With Celecoxib ( APC ) trial showed that the selective cyclooxygenase-2 ( COX-2 )...
Axalimogene filolisbac, a listeria-based HPV immunotherapy, in second and third-line metastatic cervical cancer
Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ),...
Advanced lung cancer: five-year survival rate for Nivolumab-treated patients much higher than historical rate
Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small...
IDO pathway inhibitor Indoximod in combination with Pembrolizumab, an anti-PD1 checkpoint inhibitor, for patients with advanced melanoma
The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In...
Metabolic disease, particularly type 2 diabetes mellitus, is correlated with having bacteria that penetrate the mucus lining of the colon
In humans, developing metabolic disease, particularly type 2 diabetes, is correlated with having bacteria that penetrate the mucus lining of...